Xencor (XNCR) Return on Capital Employed (2014 - 2026)
Xencor's (XNCR) quarterly Return on Capital Employed came in at 28.96% in Q1 2026, down 908.0% year-on-year from 3.58% in Q1 2025, and down 26.64% on a QoQ basis from 22.87% in Q4 2025.
Xencor (XNCR) Return on Capital Employed (2014 - 2026) Analysis & Trends
Xencor (XNCR) has 13 years of Return on Capital Employed data on file, last reported at 28.96% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 908.0% year-over-year to 28.96% in Q1 2026; TTM through Mar 2026 was 28.96%, a 908.0% decrease from a year earlier, with the FY2025 full-year figure at 21.7%, down 122.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 28.96%, down from 22.87% in the prior quarter.
- Over the last five years, Return on Capital Employed for XNCR reached as high as 10.91% in Q1 2022 and fell as low as 28.96% in Q1 2026.
- Historically, Return on Capital Employed has averaged 14.89% across 5 years, with a median of 19.62% in 2024.
- Across the five-year window, Return on Capital Employed surged 2491 bps in 2022 and tumbled 3325 bps in 2023, its largest moves.
- Year by year, Return on Capital Employed stood at 10.62% in 2022, then plunged by 56 bps to 16.59% in 2023, then slipped by 21 bps to 20.08% in 2024, then decreased by 14 bps to 22.87% in 2025, then dropped by 27 bps to 28.96% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 28.96% in Q1 2026, 22.87% in Q4 2025, and 17.4% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Xencor | 1.47 Bn | 1.09 Bn | - | -28.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.96% |
| Dec 31, 2025 | -22.87% |
| Sep 30, 2025 | -17.40% |
| Jun 30, 2025 | -18.18% |
| Mar 31, 2025 | -19.88% |
| Dec 31, 2024 | -20.08% |
| Sep 30, 2024 | -23.22% |
| Jun 30, 2024 | -19.62% |
| Mar 31, 2024 | -14.69% |
| Dec 31, 2023 | -16.59% |
| Sep 30, 2023 | -20.35% |
| Jun 30, 2023 | -22.47% |
| Mar 31, 2023 | -22.33% |
| Dec 31, 2022 | -10.62% |
| Sep 30, 2022 | 6.87% |
| Jun 30, 2022 | 6.26% |
| Mar 31, 2022 | 10.91% |
| Dec 31, 2021 | 6.28% |
| Sep 30, 2021 | -9.44% |
| Jun 30, 2021 | -5.71% |